HDAC抑制在活检来源初治弥漫性中线胶质瘤模型中的优化靶向治疗
该研究在活检来源的初治弥漫性中线胶质瘤(DMG)体外和体内模型中测试HDAC抑制剂,发现quisinostat和romidepsin在低纳摩尔IC50值下有效,且两者均显著抑制体内肿瘤生长;转录组分析提示TNNT1过表达和COL20A1下调为潜在靶点生物标志物。
要点
- Quisinostat和romidepsin在DMG模型中显示低纳摩尔IC50值,具体外效力。
- 两药均显著抑制体内肿瘤生长(P < 0.0001)。
- TNNT1过表达和COL20A1下调为HDAC抑制的潜在应答标志物。
核心结论
- Quisinostat和romidepsin在初治活检来源DMG模型中有效,并揭示潜在生物标志物。
研究设计与样本
- 在活检来源的初治DMG体外和体内模型(具生物学相关辐射抵抗)中测试HDAC抑制剂,并行RNA测序。
主要发现
- Quisinostat和romidepsin的半数抑制浓度(IC50)分别约为50 nM和约5 nM。
- Quisinostat与panobinostat的生物学效应共享程度高于romidepsin。
- 三种药物在相似生物有效剂量下均引起TNNT1过表达和COL20A1下调。
- Quisinostat和romidepsin显著抑制体内肿瘤生长(P < 0.0001)。
临床怎么用
- 提示quisinostat和romidepsin可作为DMG候选治疗药物,但需开发能穿透脑肿瘤的版本。
局限性
- 研究使用临床前模型,尚未在患者中验证疗效与生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), have a dismal prognosis, with less than 2% surviving 5 years postdiagnosis. The majority of DIPGs and all DMGs harbor mutations altering the epigenetic regulatory histone tail (H3 K27M). Investigations addressing DMG epigenetics have identified a few promising drugs, including the HDAC inhibitor (HDACi) panobinostat. Here, we use clinically relevant DMG models to identify and validate other effective HDACi and their biomarkers of response. METHODS: HDAC inhibitors were tested across biopsy-derived treatment-naïve in vitro and in vivo DMG models with biologically relevant radiation resistance. RNA sequencing was performed to define and compare drug efficacy and to map predictive biomarkers of response. RESULTS: Quisinostat and romidepsin showed efficacy with low nanomolar half-maximal inhibitory concentration (IC50) values (~50 and ~5 nM, respectively). Comparative transcriptome analyses across quisinostat, romidepsin, and panobinostat showed a greater degree of shared biological effects between quisinostat and panobinostat, and less overlap with romidepsin. However, some transcriptional changes were consistent across all 3 drugs at similar biologically effective doses, such as overexpression of troponin T1 slow skeletal type (TNNT1) and downregulation of collagen type 20 alpha 1 chain (COL20A1), identifying these as potential vulnerabilities or on-target biomarkers in DMG. Quisinostat and romidepsin significantly (P < 0.0001) inhibited in vivo tumor growth. CONCLUSIONS: Our data highlight the utility of treatment-naïve biopsy-derived models; establishes quisinostat and romidepsin as effective in vivo; illuminates potential mechanisms and/or biomarkers of DMG cell lethality due to HDAC inhibition; and emphasizes the need for brain tumor-penetrant versions of potentially efficacious agents.
引用
- Vitanza NA, Biery MC, Myers C, et al. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. Neuro Oncol. 2021. PMID: 33130903. doi:10.1093/neuonc/noaa249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。